{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:25:45Z","timestamp":1791689145193,"version":"4.3.4"},"reference-count":22,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2021,4,1]]},"DOI":"10.1001\/jamaoncol.2020.7857","type":"journal-article","created":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T23:37:21Z","timestamp":1613864241000},"page":"555","source":"Crossref","is-referenced-by-count":132,"title":["Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer"],"prefix":"10.1001","volume":"7","author":[{"given":"Adnan","family":"Ali","sequence":"first","affiliation":[{"name":"Genito-Urinary Cancer Research Group, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom"},{"name":"FASTMAN Centre of Excellence, Manchester Cancer Research Centre, Manchester, United Kingdom"},{"name":"Department of Surgery, The Christie NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Hoyle","sequence":"additional","affiliation":[{"name":"Genito-Urinary Cancer Research Group, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom"},{"name":"FASTMAN Centre of Excellence, Manchester Cancer Research Centre, Manchester, United Kingdom"},{"name":"Department of Surgery, The Christie NHS Foundation Trust, Manchester, United Kingdom"},{"name":"Department of Urology, The Salford NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ine M.","family":"Haran","sequence":"additional","affiliation":[{"name":"Genito-Urinary Cancer Research Group, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom"},{"name":"FASTMAN Centre of Excellence, Manchester Cancer Research Centre, Manchester, United Kingdom"},{"name":"Department of Surgery, The Christie NHS Foundation Trust, Manchester, United Kingdom"},{"name":"Department of Urology, The Salford NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Brawley","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Cook","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Amos","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Calvert","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Douis","sequence":"additional","affiliation":[{"name":"Department of Radiology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm D.","family":"Mason","sequence":"additional","affiliation":[{"name":"Cardiff University, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dearnaley","sequence":"additional","affiliation":[{"name":"Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhardt","family":"Attard","sequence":"additional","affiliation":[{"name":"UCL Cancer Institute, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[{"name":"Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom"},{"name":"Oncology Institute of Southern Switzerland, Bellinzona, Switzerland"},{"name":"Universit\u00e0 della Svizzera Italiana, Lugano, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh K. B.","family":"Parmar","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Parker","sequence":"additional","affiliation":[{"name":"Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Sydes","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas D.","family":"James","sequence":"additional","affiliation":[{"name":"Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel W.","family":"Clarke","sequence":"additional","affiliation":[{"name":"Genito-Urinary Cancer Research Group, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom"},{"name":"FASTMAN Centre of Excellence, Manchester Cancer Research Centre, Manchester, United Kingdom"},{"name":"Department of Surgery, The Christie NHS Foundation Trust, Manchester, United Kingdom"},{"name":"Department of Urology, The Salford NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10162","key":"coi200113r1","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"coi200113r2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","article-title":"Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis.","volume":"76","author":"Burdett","year":"2019","journal-title":"Eur Urol"},{"issue":"3","key":"coi200113r3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","article-title":"Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial.","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol"},{"issue":"9","key":"coi200113r6","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"issue":"4","key":"coi200113r7","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.eururo.2020.01.012","article-title":"Management of patients with advanced prostate cancer: report of the Advanced Prostate Cancer Consensus Conference 2019.","volume":"77","author":"Gillessen","year":"2020","journal-title":"Eur Urol"},{"issue":"5","key":"coi200113r8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0090-4295(89)90107-6","article-title":"Prognostic factors in patients with advanced prostate cancer.","volume":"33","author":"Soloway","year":"1989","journal-title":"Urology"},{"issue":"4","key":"coi200113r9","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer.","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"coi200113r10","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer.","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"coi200113r11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan.","volume":"61","author":"Soloway","year":"1988","journal-title":"Cancer"},{"issue":"11","key":"coi200113r12","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial.","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"issue":"16","key":"coi200113r13","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1002\/(ISSN)1097-0258","article-title":"A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials.","volume":"23","author":"Royston","year":"2004","journal-title":"Stat Med"},{"issue":"11","key":"coi200113r15","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/jnci\/86.11.829","article-title":"Dangers of using \u201coptimal\u201d cutpoints in the evaluation of prognostic factors.","volume":"86","author":"Altman","year":"1994","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"coi200113r16","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1001\/jamaoncol.2015.4350","article-title":"Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial.","volume":"2","author":"James","year":"2016","journal-title":"JAMA Oncol"},{"issue":"4S","key":"coi200113r17","article-title":"The importance of lymph node location, burden and treatment outcome in M1 HSPC: analysis from the STAMPEDE trial arms A and C.","volume":"203","author":"Haran","year":"2020","journal-title":"J Urol"},{"issue":"1","key":"coi200113r18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/nrurol.2016.175","article-title":"Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations.","volume":"14","author":"Tosoian","year":"2017","journal-title":"Nat Rev Urol"},{"issue":"6","key":"coi200113r19","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1097\/MOU.0000000000000675","article-title":"Prostate radiotherapy in newly diagnosed metastatic prostate cancer.","volume":"29","author":"Ali","year":"2019","journal-title":"Curr Opin Urol"},{"issue":"7547","key":"coi200113r20","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nature14347","article-title":"The evolutionary history of lethal metastatic prostate cancer.","volume":"520","author":"Gundem","year":"2015","journal-title":"Nature"},{"issue":"13","key":"coi200113r21","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1158\/1078-0432.CCR-20-0168","article-title":"Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer.","volume":"26","author":"Stopsack","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"4","key":"coi200113r22","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.euo.2020.05.003","article-title":"The automated bone scan index as a predictor of response to prostate radiotherapy in men with newly diagnosed metastatic prostate cancer: an exploratory analysis of STAMPEDE\u2019s \u201cM1 RT Comparison\u201d.","volume":"3","author":"Ali","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"coi200113r14","doi-asserted-by":"crossref","DOI":"10.1002\/9780470770771","volume-title":"Multivariable Model-Building: A Pragmatic Approach to Regression Analysis Based on Fractional Polynomials for Modelling Continuous Variables","author":"Royston","year":"2008"},{"key":"coi200113r4","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: prostate cancer. Version 2.2019. Accessed March 7, 2019. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf"},{"key":"coi200113r5","unstructured":"Mottet? N, Bellmunt? J, Briers? E, ; members of the EAU\u2013ESTRO\u2013ESUR\u2013SIOG Prostate Cancer Guidelines Panel. EAU\u2013ESTRO\u2013ESUR\u2013SIOG guidelines on prostate cancer. Accessed March 13, 2019. https:\/\/uroweb.org\/guideline\/prostate-cancer\/"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2776418\/jamaoncology_ali_2021_oi_200113_1617385021.78094.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T03:17:12Z","timestamp":1618629432000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2776418"}},"subtitle":["A Secondary Analysis of a Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2020.7857","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4,1]]}}}